Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;19(2):131-148.
doi: 10.1038/s41573-019-0048-x. Epub 2019 Nov 20.

Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models

Richard J Weaver  1 , Eric A Blomme  2 , Amy E Chadwick  3 , Ian M Copple  3 , Helga H J Gerets  4 , Christopher E Goldring  3 , Andre Guillouzo  5 , Philip G Hewitt  6 , Magnus Ingelman-Sundberg  7 , Klaus Gjervig Jensen  8 , Satu Juhila  9 , Ursula Klingmüller  10 , Gilles Labbe  11 , Michael J Liguori  2 , Cerys A Lovatt  12 , Paul Morgan  13 , Dean J Naisbitt  3 , Raymond H H Pieters  14 , Jan Snoeys  15 , Bob van de Water  16 , Dominic P Williams  13 , B Kevin Park  17
Affiliations
Free article
Review

Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models

Richard J Weaver et al. Nat Rev Drug Discov. 2020 Feb.
Free article

Abstract

Drug-induced liver injury (DILI) is a patient-specific, temporal, multifactorial pathophysiological process that cannot yet be recapitulated in a single in vitro model. Current preclinical testing regimes for the detection of human DILI thus remain inadequate. A systematic and concerted research effort is required to address the deficiencies in current models and to present a defined approach towards the development of new or adapted model systems for DILI prediction. This Perspective defines the current status of available models and the mechanistic understanding of DILI, and proposes our vision of a roadmap for the development of predictive preclinical models of human DILI.

PubMed Disclaimer

References

    1. Ostapowicz, G. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137, 947–954 (2002). - PubMed
    1. Atienzar, F. A. et al. Key challenges and opportunities associated with the use of in vitro models to detect human DILI: integrated risk assessment and mitigation plans. Biomed. Res. Int. 2016, 9737920 (2016). - PubMed - PMC
    1. Fung, M. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets—1960 to 1999. Drug Inf. J. 35, 293–317 (2001).
    1. Chen, M. et al. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov. Today 16, 697–703 (2011). - PubMed
    1. Thakkar, S. et al. The liver toxicity knowledge base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury. Expert Rev. Gastroenterol. Hepatol. 12, 31–38 (2018). - PubMed

Publication types

MeSH terms